Whole-body PBPK model of cyclosporine as inhibitor of the breast cancer resistance protein (BCRP) transport protein.
The presented PBPK model of cyclosporine has been developed to be used in a PBPK Drug-Drug-Interactions (DDI) network with cyclosporine as inhibitor of BCRP. The development of this model is described in the publication by Schaller et al. [1]
- a PK-Sim project file of the current PBPK model
- a PK-Sim snapshot (*.json) file of the current PBPK model
PK-Sim Version 9.1
Everyone interacting in the Open Systems Pharmacology community (codebases, issue trackers, chat rooms, mailing lists etc...) is expected to follow the Open Systems Pharmacology code of conduct.
We encourage contribution to the Open Systems Pharmacology community. Before getting started please read the contribution guidelines. If you are contributing code, please be familiar with the coding standard.
The model code is distributed under the GPLv2 License.
[1] Schaller, S., Michon, I., Baier, V. et al. Evaluation of BCRP-Related DDIs Between Methotrexate and Cyclosporin A Using Physiologically Based Pharmacokinetic Modelling. Drugs R D (2024). https://doi.org/10.1007/s40268-024-00495-1